Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease

Future Cardiology

Volumn 6, Issue 5, 2010, Pages 657-691

  Azhar, Salman ^a  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

atherosclerosis; diabetes; dyslipidemia; fibrates; inflammation; insulin resistance; metabolic diseases; PPAR agonists; thiazolodinediones

Indexed keywords

2 [4 [2 [3 (2,4 DIFLUOROPHENYL) 1 HEPTYLUREIDO]ETHYL]PHENYLTHIO] 2 METHYLPROPIONIC ACID; 2 [4 [2 [3 CYCLOHEXYL 1 (4 CYCLOHEXYLBUTYL)UREIDO]ETHYL]PHENYLTHIO] 2 METHYLPROPIONIC ACID; 2 [4 [3 [4,5 DIHYDRO 1 (4 METHYLBENZYL) 5 OXO 1H 1,2,4 TRIAZOL 3 YL]PROPYL]PHENOXY] 2 METHYLPROPIONIC ACID; 4 [4 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY)PROPOXY]PHENOXY]ACETIC ACID; 5 (2,4 DIOXO 5 THIAZOLIDINYLMETHYL) 2 METHOXY N [4 (TRIFLUOROMETHYL)BENZYL]BENZAMIDE; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; [4 [2 (3 FLUORO 4 TRIFLUOROMETHYLPHENYL) 4 METHYL 5 THIAZOLYLMETHYLTHIO] 2 METHYLPHENOXY]ACETIC ACID; AMG 131; AVE 0847; AVE 8134; AZD 6610; BALAGLITAZONE; BEZAFIBRATE; CIGLITAZONE; CIPROFIBRATE; CLOFIBRATE; CS 038; DPM 204; DRF 10945; DRL 11605; FENOFIBRATE; FK 614; GEMCOR; GEMFIBROZIL; GW 0072; GW 2433; GW 50516; GW 590735; GW 610742; GW 625019; GW 677954; INT 131; KR 62980; LY 465608; MBX 10; MBX 2044; METAGLIDASEN; METFORMIN; MK 0533; MURAGLITAZAR; PA 082; PAT 5A; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PGX 510; PIOGLITAZONE; PIRINIXIC ACID; PLX 204; RIVOGLITAZONE; ROSIGLITAZONE; RWJ 348260; S 26948; SULFONYLUREA; T 913659; TESAGLITAZAR; TROGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ATHEROSCLEROSIS; BONE MARROW DISEASE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DYSLIPIDEMIA; EDEMA; FRACTURE; HEADACHE; HEART FAILURE; HEART INFARCTION; HEART MUSCLE METABOLISM; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOGLYCEMIA; INFLAMMATION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIPID METABOLISM; LIVER TOXICITY; LOW DRUG DOSE; METABOLIC SYNDROME X; MYALGIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SIDE EFFECT; STROKE; VASCULARIZATION; WEIGHT GAIN;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; ENDOTHELIUM, VASCULAR; FIBRIC ACIDS; HUMANS; HYPERTENSION; INFLAMMATION; LIPID METABOLISM; METABOLIC SYNDROME X; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PEROXISOME PROLIFERATORS; RISK FACTORS; THIAZOLIDINEDIONES;

EID: 77958060003     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.10.86     Document Type: Review

References (270)

1. Plump AS, Lum PY: Genomics and cardiovascular drug development. J. Am. Coll. Cardiol. 53, 1089-1100 (2009).
2. Weiner SD, Rabbani LE: Secondary prevention strategies for coronary heart disease. J. Throm. Thrombolysis 29(1), 8-24 (2010).
3. Rosamond W, Flegal K, Furie K et al.: Heart disease and stroke statistics: 2008 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117, e25-e146 (2008).
4. Lloyd-Jones D, Adams R, Carnethon M et al.: Heart disease and stroke statistics-2009 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 119, 480-486 (2009).
5. Poirier P, Giles TD, Bray GA et al.: Obesity and cardiovascular diseases: Pathophysiology, evaluation and effect of weight loss: An update of the 1997 American Heart Association Statement on Obesity and Heart Disease From the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 113, 898-918 (2006).
6. Aronne LJ, Isoldi KK: Overweight and obesity: Key components of cradiometabolic risk. Clin. Cornerstone 8, 29-37 (2007).
7. Lavie CJ, Milani RV, Ventura HO: Obesity and cardiovascular disease: Risk factor, paradox, and impact of weight loss. J. Am. Coll. Cardiol. 53, 1925-1932 (2009).
8. Ginsberg HN, MacCallum PR: The obesity, metabolic syndrome, and Type 2 diabetes mellitus pandemic: Part I: Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and Type 2 diabetes mellitus. J. Cardiometab. Syndr. 4, 113-119 (2009).
9. Calkin AC, Allen TJ: Diabetes mellitus-associated atherosclerosis: Mechanisms involved and potential for pharmacological invention. Am. J. Cardiovasc Drugs 61, 15-40 (2006).
10. Smith SC: Multiple risk factors for cardiovascular disease and diabetes mellitus. Am. J. Med. 120, S3-S11 (2007).
11. Deshpande AD, Harris-Hays M, Schootman M: Epidemiology of diabetes and diabetes-related complications. Phys. Ther. 88, 1254-1264 (2008).
12. Haslam DW, James WP: Obesity. Lancet 366, 107-209 (2005).
13. Wyatt SB, Winters KP, Dubbert PM: Overweight and obesity: Prevalence, consequences, and causes of a growing public health problem. Am. J. Med. Sci. 331, 166-174 (2006).
14. Pradhan A: Obesity, metabolic syndrome, and Type 2 diabetes: Inflammatory basis of glucose metabolic disorders. Nutr. Rev. 65, S152-S156 (2007).
15. Muoio DM, Newgard CB: Mechanisms of disease: Molecular and metabolic mechanisms of insulin resistance and b-cell failure in Type 2 diabetes. Nat. Rev. Mol. Cell. Biol. 9, 193-205 (2008).
16. Levesque J, Lamarche B: The metabolic syndrome: Definitions, prevalence and mangement. J. Nutrigenet. Nutrigenomics 1, 100-108 (2008).
17. Lien LF, Guyton JR: Metabolic syndrome. Dermatol. Ther. 21, 362-375 (2008).
18. Azhar S, Kelley G: PPARa: Its role in the human metabolic syndrome. Future Lipidol. 2, 31-53 (2007).
19. Grundy SM: Cleeman JI, Daniels SR et al.: Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112, 2735-2752 (2005).
20. Grundy SM: Metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 28, 629-636 (2008).
21. Alberti KG, Eckel RH, Grundy SM et al.: Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120, 1640-1645 (2009).
22. Miranda PJ, DeFronzo RA, Califf RM: Metabolic syndrome: Definition, pathophysiology, and mechanisms. Am. Heart J. 149, 33-45 (2005).
23. Reaven GM: Insulin resistance, the insulin resistance syndrome, and cardiovascular disease. Panminerva Med. 47, 201-210 (2005).
24. Cornier MA, Dabelea D, Hernandez TL et al.: The metabolic syndrome. Endocr. Rev. 29, 777-822 (2008).
25. Bruce KD, Byrne CD: The metabolic syndrome: Common origins of a multifactorial disorder. Postgrad. Med. J. 85, 614-621 (2009).
26. Potenza MV, Mechanick JI: The metabolic syndrome: Definition, global impact, and pathophysiology. Nutr. Clin. Pract. 24, 560-577 (2009).
27. Khashab MA, Liangpunsakul S, Chalasani N: Nonalcoholic fatty liver disease as a component of the metabolic syndrome. Curr. Gastroenterol. Rep. 10, 73-80 (2008).
28. Apridonidze T, Essah PA, Luorno MJ, Nestler JE: Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 90, 1929-1935 (2005).
29. Jerico C, Knobel H, Montero M et al.: Metabolic syndrome among HIV-infected patients: Prevalence, characteristics, and related factors. Diabetes Care 28, 132-137 (2005).
30. Poyhiwala P, Jain SK, Yaturu S: Metabolic syndrome and cancer. Metab. Syndr. Relat. Disord. 7, 279-288 (2009).
31. Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications: Part 1. Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet. Metab. 15, 539-553 (1998).
32. Balkau B, Charles MA: Comment on the provisional report from the WHO consultation: European Group for the Study of insulin Resistance (EGIR). Diabet. Med. 16, 442-443 (1999).
33. Executive summary of the third report of the Nationnal Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285, 2486-2497 (2001).
34. Grudy SM, Brewer HB Jr, Cleeman JI et al.: Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109, 433-438 (2004).
35. Grundy SM, Cleeman JI, Daniels SR et al.: Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112, 2735-2752 (2005).
36. Einhorn D, Reaven GM, Cobin RH et al.: American College of Endocrinology position statement on the insulin resistance syndrome. Endocr. Pract. 9, 237-252 (2003).
37. Alberti KG, Zimmet P, Shaw J: The metabolic syndrome - a new worldwide definition. Lancet 366, 1059-1062 (2005). (Pubitemid 41338752)
38. Misra A, Khurana L: Obesity and the metabolic syndrome in developing countries. J. Clin. Endocrinol. Metab. 93, S9-S30 (2008).
39. Batsis JA, Nieto-Martinez RE, Lopez-Jimenez F: Metabolic syndrome: From global epidemiology to individualized medicine. Clin. Pharmacol. Ther. 82, 509-524 (2007).
40. Spinler SA: Challenges associated with metabolic syndrome. Pharmacotherapy 26, 209S-217S (2006).
41. Epidemiology of paediatric metabolic syndrome and Type 2 diabetes mellitus. Diab. Vasc. Dis. Res. 4, 285-296 (2007).
42. Zimmet P, Alberti KG, Kaufman F et al.: The metabolic syndrome in children and adolescents - an IDF consensus report. Pediatr. Diabetes 8, 299-306 (2007).
43. Ford ES, Li C, Zhao G, Pearson WS, Mokad AH: Prevalence of the metabolic syndrome among US adolescents using the definition from the Internatioanl Diabetes Federation. Diabetes Care 31, 587-589 (2008).
44. Lefebvre P, Chinetti G, Fruchart JC, Staels B: Sorting out the roles of PPARa in energy metabolism and vascular homeostasis. J. Clin. Invest. 116, 571-580 (2006).
45. Barish GD, Narkar VA, Evans RM: PPARd: A dagger in the heart of the metabolic syndrome. J. Clin. Invest. 116, 590-597 (2006).
46. Semple RK, Chatterjee VK, O'Rahilly S: PPARg and human metabolic disease. J. Clin. Invest. 116, 581-589 (2006).
47. Fiege JN, Gelman L, Michalik L, Desvergne B, Wahli W: From molecular action to physiological outputs: Peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog. Lipid Res. 45, 120-159 (2006).
48. Duval C, Müller M, Kersten S: PPARa and dyslipidemia. Biochim. Biophys. Acta 1771, 961-972 (2007).
49. Tontonoz P, Spiegelman BM: Fat and beyond: The diverse biology of PPARg. Annu. Rev. Biochem. 77, 289-312 (2008).
50. Wagner KD, Wagner N: Peroxisome proliferator-activated receptor b/d (PPARb/d) acts as regulator of metabolism linked to multiple cellular functions. Pharmacol. Ther. 125, 423-435 (2010).
51. Blaschke F, Takata Y, Caglayan E, Law RE, Hsueh WA: Obesity, peroxisome proliferator-activated receptor, and atherosclerosis in Type 2 diabetes. Arterioscler. Thromb. Vasc. Biol. 26, 28-40 (2006). (Pubitemid 43732225)
52. Bensinger SJ, Tontonoz P: Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 454, 470-477 (2008).
53. Reilly SM, Lee C-H: PPARd as a therapeutic target in metabolic disease. FEBS Lett. 582, 26-31 (2008).
54. Robinson E, Grieve DJ: Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and disease. Pharmacol. Ther. 122, 246-263 (2009).
55. Berger JP, Akiyama TE, Meinke PT: PPARs: Therapeutic targets for metabolic disease. Trends Pharmacol. Sci. 26, 244-251 (2005).
56. Brown JD, Plutzky J: Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. Circulation 115, 518-533 (2007).
57. Hansen MK, Connolly TM: Nuclear receptors as drug targets in obesity, dyslipidemia and atherosclerosis. Curr. Opin. Investig. Drug. 9, 247-255 (2008).
58. Barter PJ, Rye K-A: Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome? Arterioscler Thromb. Vasc. Biol. 28,39-46 (2008).
59. Remick J: Weintraub H, Setton R et al.: Fibrate therapy: An update. Cardiol. Rev. 16, 129-141 (2008).
60. Yki-Järvinen H: Thiazolidinediones. N. Engl. J. Med. 35, 1106-1118 (2004).
61. Barnett AH: Redefining the role of thiazolidinediones in the management of Type 2 diabetes. Vasc. Health Risk Manag. 5, 141-151 (2009).
62. Sprecher DL, Massien C, Pearce G et al.: Triglyceride: High-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor d agonist. Arterioscler. Thromb. Vasc. Biol. 27, 359-365 (2007).
63. Risérus U, Sprecher D, Johnson T et al.: Activation of peroxisome proliferator-activated receptor (PPAR) d promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men. Diabetes 57, 332-339 (2008).
64. Bookout AL, Jeong Y, Downes M, Yu RT, Evans RM, Mangelsdorf DJ: Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. Cell 126, 789-799 (2006).
65. Michalik L, Auwerx J, Berger JP et al.: International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol. Rev. 58(4), 726-741 (2006).
66. Guo L, Tabrizchi R: Peroxisome proliferator-activated receptor g as a drug target in the pathogenesis of insulin resistance. Pharmacol. Ther. 111, 145-173 (2006).
67. Gurevich I, Flores AM, Aneskievich BJ: Corepressors of agonist bound nuclear receptors. Toxicol. Appl. Pharmacol. 223, 288-298 (2007).
68. Yu S, Reddy JK: Transcription coactivators for peroxisome proliferator-activated receptors. Biochim. Biophys. Acta 1771, 936-951 (2007).
69. Gozalez FJ, Shah YM: PPARa: Mechansim of species differences and hepatocarcinogenesis of peroxisome proliferators. Toxicology 246, 2-8 (2008).
70. Pyper SR, Viswakarma N, Yu S, Reddy JK: PPARa: Energy combustion, hypolipidemia, inflammation and cancer. Nucl. Recep. Signal. 8, 2002 (2010).
71. Hamblin M, Chang L, Fan Y, Zhang J, Chen YE: PPARs and the cardiovascular system. Antioxid. Redox Signal. 11, 1-38 (2009).
72. Dayspring T, Pokrywka G: Fibrate therapy in patients with metabolic syndrome and diabetes mellitus. Curr. Atheroscler. Rep. 8, 356-364 (2006).
73. Fruchart J-C: Peroxisome proliferator-activated receptor-a (PPARa): At the crossroads of obesity, diabetes and cardiovascular disease. Atherosclerosis 205, 1-8 (2009).
74. Muoio DM, Newgard CB: Obesity-related derangements in metabolic regulation. Annu. Rev. Biocem. 75, 367-401 (2006).
75. Naito H, Yamanoshita O, Kamijima M et al.: Association of V227A PPARa polymorphism with altered serum biochemistry and alcohol drinking in Japanese men. Pharmacogenet. Genomics 16, 569-577 (2006).
76. Yong EL, Li J, Liu MH: Single gene contributions: Genetic variants of proliferator-activated receptor (isoforms a, b/d and g) and mechanisms of dyslipidemias: Curr. Opin. Lipidol. 19, 106-112 (2008).
77. Liu MH, Li J, Shen P, Husna B, Tai ES, Yong EL: A natural polymorphism in the peroxisome prolifertaor-activated receptor-a hinge region attenuates transcription due to defective release of nuclear receptor coreprssor from chromatin. Mol. Endocrinol. 22, 1078-1092 (2008).
78. Chan E, Tan CS, Deurenberg-Yap M, Chia KS, Chew SK, Tai ES: The V227A polymorphism at the PPARA locus is associated with serum lipid concentrations and modulates the association between dietary polyunsaturated fatty acid intake and serum high density lipoprotein concentrations in Chinese women. Atherosclerosis 187, 309-315 (2006).
79. Sparsø T, Hussain MS, Andersen G et al.: Relationships between the functional PPARa Leu162Val polymorphism and obesity, Type 2 diabetes, dyslipidemia, and related quantitative traits in studies of 5799 middle-aged white people. Mol. Genet. Metab. 90, 205-209 (2007).
80. Tanaka T, Ordovas JM, Delgado-Lista J et al.: Peroxisome proliferator-activated receptor a polymorphisms and postprandial lipemia in healthy men. J. Lipid Res. 48, 1402-1408 (2007).
81. Uthurralt J, Gordish-Dressman H, Bradbury M et al.: PPARa L162V underlies variation in serum triglycerides and subcutaneous fat volume in young males. BMC Med. Genet. 8, 55 (2007).
82. Rudkowska I, Verrault M, Barbier O, Vohl M-C: Differences in transcription activation by the two allelic (L162V polymorphic) variants of PPARa after omega-3 fatty acid treatment. PPAR Res. 369602 (2009).
83. Silbernagel G, Stefan N, Hoffmann MM et al.: The L162V polymorphism of the peroxisome proliferator activated receptor a gene (PPAR) is not associated with Type 2 diabetes, BMI or body fat composition. Exp. Clin. Endocrinol. Diabetes 117, 113-118 (2009).
84. Doney AS, Fischer B, Lee SP, Morris AD, Leese G, Palmer CN: Association of common variation in the variation in the PPARa gene withincident myocardial infarction in individuals with Type 2 diabetes: A Go-DARTS study. Nucl Recept 3, 4 (2005).
85. Finck BN: The PPAR regulatory system in cardiac physiology and disease. Cardiovasc. Res. 73, 269-277 (2007).
86. Yang Q, Li Y: Roles of PPARs on regulating myocardial energy and lipid homeostasis. J. Mol Med. 85,697-706 (2007).
87. Madarazo JA, Kelley DP: The PPAR trio: Regulators of mitochondrial energy metabolism in health and disease. J. Mol. Cell. Cardiol. 44, 968-975 (2008).
88. Barak Y, Kim S: Genetic manipulations of PPARs: Effects on obesity and metabolic disease: PPAR Res. 12781 (2007).
89. Park SY, Cho YR, Finck BM et al.: Cardiac-specific overexpression of peroxisome proliferator-activated receptor-a causes insulin resistance in heart and liver. Diabetes 54, 2514-2524 (2005).
90. Sambandhan N, Morabito D, Wagg C, Finck BN, Kelly DP, Lopaschuk GD: Chronic activation of PPARa is detrimental to cardiac recovery after ischemia. Am. J. Physiol. Heart Circ. Physiol. 290, H87-H95 (2006).
91. Duncan JG, Fong JL, Mederiros DM, Finck BN, Kelley DP: Insulin-resistant heart exhibits a mitochondrial biogenic response driven by the peroxisome proliferator-activated receptor-a/PGC-1a gene regulatory pathway. Circulation 115, 909-917 (2007).
92. Wang J, Song Y, Wang Q, Kralik PM, Epstein PN: Causes and characteristics of diabetic cardiomyopathy. Rev Diabt Stud. 3, 108-117 (2005).
93. Panagia M, Gibbons GF, Radda GK, Clarke K: PPAR-a activation required for decreased glucose uptake and increased susceptibility to injury during ischemia. Am. J. Physiol. Heart Circ. Physiol. 288, H2677-H2683 (2005).
94. Loichot C, Jesel L, Tesse A et al.: Deletion of peroxisome proliferator-activated receptor-a induces an alteration of cardiac functions. Am. J. Physiol. Heart Circ. Physiol. 291, H161-H166 (2006).
95. Gélinas R, Labarthe F, Bouchard B et al.: Alterations in carbohydrate metabolism and its regulation in PPARa null mouse hearts. Am. J. Physiol. Heart Circ. Physiol. 294, H1571-H1580 (2008).
96. Sweets PJH, Teunissen BEJ, Willemsen PHM et al.: Cardiac hypertrophy is enhanced in PPARa-/- mice in response to chronic pressure overload. Cardiovas. Res. 78, 79-89 (2008).
97. Schiffrin EL: Peroxisome proliferator-activated receptors and cardiovascular remodeling. Am. J. Physiol. Heart Circ. Physiol. 288, H1037-H1043 (2005).
98. Moraes L, Piqueras L, Bishop-Bailey D: Peroxisome proliferator-activated receptors and inflammation. Pharmacol. Ther. 110, 371-385 (2006).
99. Zandbergen F, Plutzky J: PPARa in atherosclerosis and inflammation. Biochim. Biophys. Acta. 1771, 972-982 (2007).
100. Brown JD, Plutzky J: Peroxisome proliferator-activated receptors as transcription nodal points and therapeutic targets. Circulation 115, 518-533 (2007).
101. Marx N, Duez H, Fruchart JC, Staels B: Peroxisome proliferator-activated receptors and atherogenesis: Regulators of gene expression in vascular cells. Circ. Res. 94, 1168-1178, (2004).
102. Chinetti-Gbaguidi G, Rigamonti E, Helin L et al.: Peroxisome proliferator-activated a controls cellular cholesterol trafficking in macrophages. J. Lipid Res. 46, 2717-2725 (2005). (Pubitemid 43107484)
103. Hennuyer N, Tailleux A, Torpier G et al.: PPARa, but not PPARg, activators decrease macrophage-lawn atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia. Arterioscler. Thromb. Vasc. Biol. 25, 1897-1902 (2005).
104. Li AC, Binder CJ, Gutierrez A et al.: Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARa, b/d, and g. J. Clin. Invest. 114, 1564-1576 (2004).
105. Babaev VR, Ishiguro H, Ding L et al.: Macrophage expression of peroxisome proliferator-activated receptor-a reduces atherosclerosis in low-density lipoprotein-deficient mice. Circulation 116, 1404-1412 (2007).
106. Barish GD, Nakar V, Evans RM: PPARd: A dagger in the heart of metabolic syndrome. J. Clin. Invest. 116, 590-597 (2006).
107. Kilgore KS, Billin A: PPARb/d ligands as modulators of the inflammatory response. Curr. Opin. Investig. Drugs 9, 463-469 (2008).
108. Bishop-baily D, Bystrom J: Emerging roles of peroxisome proliferator-activated receptor-b/d in inflammation. Pharmacol. Ther. 124, 141-150 (2009).
109. Oliver WR, Shenk JL, Snaith MR et al.: A selective peroxisome proliferator-activated receptor d agonist promotes reverse cholesterol transport. Proc. Natl Acad. Sci. USA 98, 5305-5311.
110. Wallace JM, Schwarz M, Coward P et al.: Effects of peroxisome proliferator-activated receptor a/d agonists on HDL-cholesterol in vervet monkeys. J. Lipid Res. 46, 1009-1016 (2005).
111. Barish GD, Atkins AR, Downes M et al.: PPARd regulates multiple proinflammatory pathways to suppress atherosclerosis. Proc. Natl Acad. Sci. USA 105, 4271-4276 (2008).
112. Tokata Y, Liu J, Fen Y et al.: PPARd-mediated anti-inflammatory mechanisms inhibit angiotensin II-accelerated atherosclerosis. Proc. Natl Acad, Sci. USA 105, 4277-4282 (2008).
113. Takahashi S, Tanaka T, Sakai J: New therapeutic target for metabolic syndrome. Endocr. J. 54, 347-357 (2007).
114. Kang K, Hatano B, Lee C-H: PPARd agonists and metabolic diseases: Curr. Atheroscler. Rep. 9, 72-77 (2007).
115. Ehrenborg E, Krook A: Regulation of skeletal muscle physiology and metabolism by peroxisome proliferator-activated receptor d. Pharmacol.Rev. 61, 373-393 (2009).
116. van der Veen JN, Kruit JK, Havinga R et al.: Reduced cholesterol absorption upon PPARd activation coincides with decreased intestinal expression of NPC1L1. J. Lipid Res. 46, 526-534 (2005).
117. Akiyama TE, Lambert G, Nicol CJ: Et al.: Peroxisome proliferator b/d regulates very low density lipoprotein production and catabolism in mice on a western diet. J. Biol. Chem. 279, 20874-20881 (2004).
118. Nadra K, Anghel SI, Joye E et al.: Differentiation of trophoblast giant cells and their metabolic functions are dependent on peroxisome proliferator-activated receptor b(d). Mol. Cell. Biol. 26, 3266-3281 (2006).
119. Lee CH, Olson P, Hevener A et al.: PPARd regulates glucose metabolism and insulin sensitivity. Proc. Natl Acad. Sci. USA 103, 3444-3449 (2006).
120. Kang K, Reilly SM, Karabacak V et al.: Adipocyte-derived TH2 cytokines and myeloid PPARd regulate macrophage polarization and insulin sensitivity. Cell Metab. 7, 485-495 (2008).
121. Odegaard JI, Richardo-Gonzalez RR, Eagle AR et al.: Alternative M2 activation of Kupffer cells by PPARd ameliorates obesity- induced insulin resistance. Cell Metab. 7, 496-507 (2008).
122. Desvergne B: PPARd/b: The lobbyist switching macrophage allegiance in favor of metabolism. Cell Metab. 7, 467-469 (2008).
123. Cheng L, Ding G, Qin Q et al.: Cardiomyocyte-restricted peroxisome proliferator-activated receptor-d deletion pertubs myocardial fatty acid oxidation and leads to cardiomyopathy. Nat. Med. 10, 1245-1250 (2004).
124. Cheng LY, Qin Q, Liu J, Liu J, Lo WK, Brako LA, Yang Q: High-fat feeding in cardiomyocyte-restricted PPARd knockout mice leads to cardiac overexpression of lipid metabolic genes but fails to rescue cardiac phenotypes. J. Mol. Cell. Cardiol. 47, 536-543 (2009).
125. Burkat EM, Sambandam N, Han X et al.: Nuclear receptors PPARb/d and PPARa direct distinct metabolic regulatory programs in the mouse heart. J. Clin. Invest. 117, 3930-3939 (2007).
126. Wang YX, Zhang CL, Yu RT et al.: Regulation of muscle fiber type and running endurance by PPARd. PLoS Biol. 2, 1532-1539 (2004).
127. Sprecher DL: Lipids, lipoproteins, and peroxisome proliferator activated receptor d. Am. J. Cardiol. 100(11A), N20-N24 (2007).
128. Reilly SM, Lee C-H: PPARd as a therapeutic target in metabolic disease. FEBS. Lett. 582, 26-31 (2008).
129. Aberle J, Hopfer I, Beil FU, Seedorf U: Association of the T+294C polymorphism in PPAR d with low HDL cholesterol and coronary heart disease risk in women. Int. J. Med. Sci. 3,108-111 (2006).
130. Grarup N, Albrechtsen A, Ek J et al.: Variation in the peroxisome proliferator-activated receptor d gene in relation to common metabolic traits in 7,495 middle-aged white people. Diabetologia 50, 1201-1208 (2007).
131. Hautala AJ, Leon AS, Skinner JS, Rao DC, Bouchard C, Rankinen T: Peroxisome proliferator-activated receptor-d polymorphisms are associated with physical performance and plasma lipids: The HERITAGE Family Study. Am. J. Physiol. Heart Circ. Physiol. 292, H2498-H2505 (2007).
132. Robitaille J, Gaudet D, Pérusse L, Vohl MC: Features of the metabolic syndrome are modulated by an interaction between the peroxisome proliferator-activated receptor d -87T>C polymorphism and dietary fat in French-Canadians. Int. Obes (Lond). 31, 411-417 (2007).
133. Thamer C, Machann J, Stefan N et al.: Variations in PPARD determine the change in body composition during lifestyle intervention: A whole-body magnetic resonance study. J. Clin. Endocrinol. Metab. 93, 1497-1500 (2008).
134. Burch LR, Donnelly LA, Doney ASF et al.: Peroxisome proliferator- activated receptor-d genotype influences metabolic phenotype and may influence lipid response to statin therapy in humans: A genetic of diabetes audit and research tayside study. J. Clin. Endocrinol. Metab. 95, 1830-1837 (2010).
135. Stefan N, Thamer C, Staiger H et al.: Genetic variations in PPARD and and PPARGC1A determine mitochondrial function and change in aerobic physical fitness and insulin sensitivity during lifestyle intervention. J. Clin Endocrinol. Metab. 92, 1827-1833 (2007).
136. Eynon N, Meckel Y, Alves AJ et al.: Is there an interaction between PPARD T294C and PPARGC1A Gly482Ser polymorphisms and human endurance performance? Exp. Physiol. 94, 1147-1152 (2009).
137. Aberle J, Hopfer I, Beil FU, Seedorf U: Assocaition of peroxisome proliferator-activated receptor d +294T/C with body mass index and interaction with peroxisome proliferator-activated receptor a 162V. Int. J. Obes. (Lond.). 30, 1709-1713 (2006).
138. Vänttinen M, Nuutila P, Kuulasmaa T, Pihlajamäki J: Single nucleotide polymorphisms in the peroxisome prolifertaor-activated receptor d gene are associated with skeletal muscle glucose uptake. Diabetes 54, 3587-3591 (2005).
139. Shin HD, Park BL, Kim LH et al.: Genetic polymorphisms in peroxisome proliferator-activated receptor d associated with obesity. Diabetes 53, 847-851 (2004).
140. Hu C, Jia W, Fan Q, Zhang R, Wang C, Lu J, Xiang K: Peroxisome proliferator-activated receptor (PPAR) d genetic polymorphism and its association with insulin resistance index and fasting plasma gluose concentrations in Chinese subjects. Diabet. Med. 23, 1307-1312 (2006).
141. Holzapfel J, Heun R, Lütjohann D, Jessen F, Maier W, Kölsch H: PPARD haplotype influences cholesterol metabolism but is no risk factor for Alzheimer's disease. Neurosci. Lett. 408, 57-61 (2006). (Pubitemid 44466201)
142. Castriloo A, Tontonoz P: Nuclear receptors in Macrophage biology: At the crossroads of lipid metabolism and inflammation. Annu. Rev. Cell. Dev. Biol. 20, 455-480 (2004).
143. Kilgore KS, Billin AN: PPARb/d ligands as modulators of the inflammatory response. Curr. Opin. Investig. Drugs 9, 463-469 (2008).
144. Fan Y, Wang Z, Tang Z: Et al.: Suppression of proinflammatory adhesion molecules by PPAR-d in human vascular endothelial cells. Arterioscler. Thromb. Vasc. Biol. 28, 315-321 (2008).
145. Piqueras L, Sanz MJ, Perretti M et al.: Activation of PPARb/d inhibits leukocyte recruitment, cell adhesion molecule expression, and chemokine release. J. Leukoc. Biol. 86, 115-122 (2009).
146. Liang YJ, Liu YC, Chen CY et al.: Comparison of PPARd and PPARg in inhibiting the proinflammatory effects of C-reactive protein in endothelial cells. Int. J. Cardiol. (2009) (Epub ahead of print).
147. Fang Y, Wang Y, Tang Z et al.: Suppression adhesion molecules by PPAR-d in vascular human and endothelial cells. Arterioscler. Thromb. Vasc. Biol. 28 315-321 (2008)
148. Lim HJ, Lee S, Park JH et al.: PPAR d agonist L-165041 inhibits rat vascular smooth muscle cell proliferation and migration via inhibition of cell cycle. Atherosclerosis 202, 446-454 (2009).
149. Kim HJ, Ham SA, Kim SU et al.: Transforming growth factor-b1 is a molecular target for the peroxisome proliferator-activated receptor d. Circ. Res. 102, 193-200 (2008).
150. Barish GD, Evans RM: PPARs and LXRs: Atherosclerosis goes nuclear: Trends Endocriol. Metab. 15, 158-1165 (2004).
151. Wang N: PPAR-d in vascular pathophysiology: PPAR Res. 164163, 1-10 (2008).
152. Graham TL, Mookherjee C, Suckling KE, Palmer CN, Patel L: The PPARd agonist GW0742X reduces atherosclerosis in LDLR (-/-) mice. Atherosclerosis 181, 29-37 (2005).
153. Zhang H, Pi R, Li R et al.: PPARb/d activation inhibits angiotensin II-induced collagen type I expression in rat cardiac fibroblasts. Arch. Biochem. Biophys. 460, 25-32 (2007).
154. Brunelli L, Cieslik A, Alcorn JL et al.: Peroxisome proliferator activated receptor-d upregulates 14-3-3 epsilon in human endothelial cells via CCAAT/enhancer binding protein-b. Circ. Res. 100, e59-e71 (2007).
155. Sprecher DL, Massien C, Pearce G et al.: Triglyceride: High-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor d agonist. Arterioscler. Thromb. Vasc. Biol. 27, 359-365 (2007).
156. Jandeleit-Dahm KAM, Calkin A, Tikellis C, Thomas M: Direct antiatherosclerotic effects of PPAR agonists. Curr. Opin. Lipidol. 20, 24-29 (2009).
157. Ahmed W, Ziouzenkova O, Brown J et al.: PPARs and their metabolic modulation: New mechanisms for transcription regulation? J. Intern. Med. 262, 184-198 (2007).
158. Guo L, Tabrizchi R: Peroxisome proliferator-activated receptor g as a drug target in the pathogenesis of insulin resistance. Pharmacol. Ther. 111, 145-173 (2006).
159. Medina-Gomez G, Gray S, Vidal-Puig A: Adipogenesis and lipotoxicity: Role of peroxisome proliferator-activated receptor g (PPARg) and PPARgcoactivator (PGC1): Public Health Nutr. 10, 1132-1137 (2007).
160. Medina-Gomez G, Virtue S, Lelliott C et al.: The link between nutritional status and insulin sensitivity is dependent on the adipocyte-specific peroxisome proliferator-activated receptor-γ2 isoform. Diabetes 54, 1706-1716 (2005).
161. Medina-Gomez G, Gray SL, Yetukuri L et al.: PPARγ2 prevents lipotoxicity by controlling adipose tissue expandability and peripheral lipid metabolism. PLoS Genet. 3, e64 (2009).
162. Christodoulides C, Vidal-Puig A: PPARs and adipocyte function. Mol. Cell. Endocrinol. 318, 1-2 (2010).
163. Chen Y, Jimenez AR, Medh JD: Identification and regulation of novel PPAR-g splice variants in human THP-1 macrophages. Biochim. Biophys. Acta. 1759, 32-43 (2006).
164. Zhou J, Wilson KM, Medh JD: Genetic analysis of four novel peroxisome proliferator activated receptor-g splice variants in monkey macrophages. Biochem. Biophys. Res. Commun. 293, 274-283 (2002).
165. Fernandez AZ: Peroxisome proliferator-activated receptors in the modulation of the immune/inflammatory response in atherosclerosis. PPAR Res. 2008, 285842 (2008).
166. Berger JP, Akiyama TE, Meinke PT: PPARs: Therapeutic target for metabolic disease. Trends Pharmacol. Sci. 26, 244-251 (2005).
167. Bhatia V, Viswanathan P: Insulin resistance and PPAR insulin sensitizers. Curr. Opin. Investig. Drugs 7, 89-897 (2006).
168. Hansen MK, Connolly TM: Nuclear receptors as drug targets in obesity, dyslipidemia and atherosclerosis. Curr. Opin. Investig. Drugs 9, 247-255 (2008).
169. Goldberg RB, Kendell DM, Deeg MA et al.: A comparison of lipid and glycemic effects on serum lipoprotein particle concentrations and sizes in patients with Type 2 diabetes and dyslipidemia. Diabetes Care. 28, 1547-1554 (2005).
170. Deeg MA, Buse JB, Goldberg RB et al.: Pioglitazone and rosiglitazone have different effects on serum lipoproparticle concentrations and sizes in patients with Type 2 diabetes and dyslipidemia. Diabetes Care. 30, 2458-2464 (2007).
171. Larsen TM, Toubro S, Astrup A: PPARg agonists in the treatment of Type II diabetes: Is increased fatness commensurate with long-term efficacy? Int. J. Obes. Relat. Metab. Disord. 27, 147-161 (2003).
172. Bergman RN, Kim SP, Hsu IR et al.: Abdominal obesity: Role in the pathophysiology of metabolic disease and cardiovascular risk. Am. J. Med. 120, S3-S8 (2007).
173. Argmann CA, Cock TA, Auwerx J: Peroxisome proliferator-activated receptor g: The more the merrier? Eur: J. Clin. Invest. 35, 82-92 (2005).
174. Ketsawatsomkron P, Pelham CJ, Groh S, Keen HL, Faraci FM, Sigmund CD: Does peroxisome proliferator-activated receptor-γ (PPARg) protect from hypertension directly through effects in the vasculature? J. Biol. Chem. 285, 9311-9316 (2010).
175. Duan SZ, Ivashchenko CY, Whitesall SE et al.: Hupotension, lipodystrophy, and insulin resistance in generalized PPARg-deficient mice rescued from embryonic lethality. J. Clin. Invest. 117, 812-822 (2007).
176. Medina-Gomez G, Gray SL, Yetukuri L et al.: PPAR γ 2 prevents lipotoxicity by controlling adipose tissue expandability and peripheral lipid metabolism. PLoS Genetics 3, e64 (2007).
177. Jeninga EH, Gurnell M, Kalkhoven E: Functional implications of genetic variation in human PPARg. Trends Endocrinol. Metab. 20, 380-387 (2009).
178. Gouda HN, Sagoo GS, Harding AH, Yates J, Sandhu MS, Higgins JPT: The association between the peroxisome proliferator-activated receptor-g2 (PPATG2) Pro12Ala gene variant and Type 2 diabetes mellitus: A HuGE review and meta analysis. Am. J. Epidemiol. 171, 645-655 (2010).
179. Heikkinen S, Argmann C, Fiege JN et al.: The pro12Ala PPARγ2 variant determines meatbolism at the gene-enviroment interface. Cell Metab. 9, 88-98 (2009).
180. Tsai YS, Kim HJ, Takahashi N et al.: Hypertension, and abnormal fat distribution but not insulin resistance in mice with P465L PPARg. J. Clin. Invest. 114, 240-249 (2004).
181. Gray SL, Dalla Nora E, Backlund EC et al.: Decreased brown adipocyte recruitment and thermogenic capacity in mice with impaired peroxisome prolifertaor-activated receptor (P465L PPARg) function. Endocrinology 147, 5708-5714 (2006).
182. Gray SL, Dalla Nora E, Grosse J et al.: Leptin deficiency unmasks the deleterious effects of impaired peroxisome proliferator-activated receptor g function (P465L PPARg) in mice. Diabetes 55, 2669-2677 (2006). (Pubitemid 44923664)
183. Beyer AM, Baumbach GL, Halabi CM et al.: Interference with PPARg signaling causes cerebral vascular dysfunction, hypertrophy, and remodeling. Hypertension 51, 867-871 (2008).
184. Verrier E, Wang L, Wadham C et al.: PPARg agonists ameliorate endothelial cell activation via inhibition of diacylglycerol-protein kinase C signaling pathway: Role of diacylglycerol kinase. Circ. Res. 94, 1515-1522 (2004).
185. Duan SH, Usher M, Mortensen RM: PPARs: The vasculature, inflammation and hypertension. Curr. Opin. Nephrol. Hyper. 18, 128-133 (2009).
186. Hwang J, Kleinhenz DJ, Lassegue B, Griendling KK, Dikalov S, Hart CM: Peroxisome proliferator-activated receptor-g ligands regulate endothelial membrane superoxide production. Am. J. Physiol. Cell Physiol. 288, C899-C905 (2005).
187. Kronke G, Kadl A, Ikonomu E et al.: Expression of heme oxygenase-1 in human vascular cells is activated by peroxisome proliferator-activated receptors. Arterioscler. Thromb. Vasc. Biol. 27, 1276-1282 (2007).
188. Bruemmer D, Blaschke F, Law RE: New targets for PPARg in the vessel wall: Implications for restenosis. Int. J. Obes. 29 (Suppl. 1), S26-S30 (2005).
189. Kuusisto J, Andrulionyte L, Laakksko M: Atherosclerosis and cardiovascular risk reduction with PPAR agonists. Curr. Atheroscler. Rep. 9, 274-280 (2007).
190. Ptasinska A, Wang S, Zhang J, Wesley RA, Danner RL: Nitric oxide activation of peroxisome proliferator-activated receptor g through a p38 MAPK signaling pathway. FASEB J. 21, 950-961 (2007).
191. Gizard F, Bruemmer D: Transcriptional control of vascular smooth muscle cell proliferation by peroxisome proliferator-activated receptor-g: Therapeutic implications for cardiovascular diseases. PPAR Res. 429123 (2008).
192. Libby P, Plutzky J: Inflammation in diabetes mellitus: Role of peroxisome proliferator-activated receptor-agonists. Am. J. Cardiol. 99 (Suppl. 99), 27B-40B (2007).
193. Brown JD, Plutzky J: Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. Circulation 115, 518-533 (2007).
194. Bouhlel MA, Derudas B, Rigamonti E et al.: PPARγ activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab. 6, 137-143 (2007).
195. Gerry JM, Pascual G: Narrowing in on cardiovascular disease: The atheroprotective role of peroxisome proliferator-activated receptor γ. Trends Cardiovasc. Med. 18, 39-44 (2008).
196. Berry A, Balard P, Coste A et al.: IL-3 induces expression of CD36 in human monocytes through PPARg activation. Eur. J. Immunol. 37, 1642-1652 (2007).
197. Odegaard JI, Ricardo-Gonzalez RR, Goforth MH et al.: Macrophage-specific PPARg controls alternative activation and improves insulin resistance. Nature 447, 1116-1120 (2007).
198. Porcheray F, Viaud S, Rimaniol AC et al.: Macrophage activation switching: An asset for the resolution of inflammation. Clin. Exp. Immunol. 142, 481-489 (2005).
199. Kendall DM, Rubin CJ, Mohideen P et al.: Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (a/g peroxisome proliferators activated receptor activator, in patients with Type 2 diabetes inadequately controlled with metformin monotherapy: A double-blinded, randomized, pioglitazone-comoartaive study. Diabetes Care 29, 1016-1023 (2005).
200. Rangwala SM, Lazar MA: Peroxisome proliferator activated receptor g in diabetes and metabolism. Trends Pharmacol. Sci. 25, 331-336 (2004).
201. Balint BL, Nagy L: Selective modulators of PPAR activity as new therapeutic tools in metabolic diseases. Endocr. Metab. Immune Disord. Drug Targets 6, 33-43 (2006).
202. Jay MA, Ren J: Peroxisome proliferator-activated receptor (PPAR) in metabolic syndrome and Type 2 diabetes mellitus. Curr. Diabetes Rev. 3, 33-39 (2007).
203. Rosenson RS: Effects of peroxisome proliferator-activated receptors on lipoprotein metabolism and glucose control in Type 2 diabetes mellitus. Am. J. Cardiol. 99, 96B-104B (2007)
204. Remick J, Weintraub H, Setton R, Offenbacher J, Fisher E, Schwartzbard A: Fibrate therapy. Cardiol. Rev. 16, 129-141 (2008).
205. Robinson J: Should we use PPAR agonists to reduce cardiovascular risk? PPAR Res. 891425, (2008).
206. Singh JP, Kauffman R, Bensch W et al.: Identification of a novel selective peroxisome proliferators-activated receptor a agonist, 2-methyl-2-(4-{3-{1-(4-methylbenzyl)-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl] propyl}phenoxy)proppanoic acid (LY618674), that produces marked changes in serum lipids and apolipoprotein A-1 expression. Mol. Pharmacol. 68, 763-768 (2005).
207. Linz W, Wohlfart P, Baader M et al.: The peroxisome proliferator- activated receptor-a (PPAR-a) agonist, AVE8134, attenuates the progression of heart failure and increases survival in rats. Acta Pharmacol. Sin. 30, 935-946 (2009).
208. Sierra ML, Benton V, Boullay A-B et al.: Substituted 2-[(4-aminomethyl) phenoxy]-2-methylpropionic acid PPARa agonists. 1. Discovey of a novel series potent HDLC raising agents. J. Med. Chem. 50, 685-695 (2007).
209. Akiyama TE, Meinke PT, Berger JP: PPAR ligands: Potential therapies for metabolic syndrome. Curr. Diab. Rep. 5, 45-52 (2005).
210. Cho N, Momose Y: Peroxisome proliferators-activated receptor g agonists as insulin sensitizers: From the discovery to recent progress. Curr. Top. Med. Chem. 8, 1483-1507 (2008).
211. Waugh J, Keating GM, Plosker GL et al.: Pioglitazone: A review of of its use in Type 2 diabetes mellitus. Drugs 66, 410-418 (2006).
212. Chang F, Jaber LA, Berlie HD, O'Connell MB: Evolution of paeroxisome proliferator-activated receptor agonists. Ann. Pharmacother. 41, 973-983 (2007).
213. Nesto RW, Bell D, Bonow RO et al.: Thiazolidinedione use, fluid retention, and congestive heart failure: A consensus statement from the American Diabetes Association. Diabetes Care 27, 256-263 (2004).
214. Cheng AYY, Fantus IG: Thiazolidinedione-induced congestive heart failure. Ann. Pharmacother. 38, 817-820 (2004).
215. Digman C, Klein AK, Pittas AG: Leukopenia and thrombocytopenia caused by thiazolidinediones. Ann. Intern. Med. 143, 465-466 (2005).
216. Hampton T: Diabetes drugs tied to fractures in women. JAMA 297, 1645 (2007).
217. Chen X, Osborne MC, Rybczynski PJ et al.: Pharmacological profile of a novel, non-TZD PPARg agonist. Diabetes Obes. Metab. 7, 536-546 (2005).
218. Carmona MC, Louche K, Lefebvre B et al.: On behalf of the consortium of the French Ministry of Research and Technology: S 26948: A new specific peroxisome proliferators-activated receptor g modulator with potent antidiabetes and antiatherogenic effects. Diabetes 56, 2797-2808 (2007).
219. Calkin AC, Forbes JM, Smith CM et al.: Rosiglitazone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects. Arterioscler. Thromb. Vasc. Biol. 25, 1903-1909 (2005).
220. Sidhu JS, Kaposzta Z, Markus HS, Kaski JC: Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients witout diabetes. Arterioscler. Thromb. Vasc. Biol. 24, 930-934 (2004).
221. Campia U, Matuskey LA, Panza JA: Peroxisome proliferators-activated receptor-g activation with pioglitazone improves endothelium dependent dialation in nondiabetic patients with major cardiovascular risk factors. Circulation 113, 867-875 (2006).
222. Meisner F, Walcher D, Gizard F et al.: Effect of rosiglitazone treatment on plaque inflammation and collagen content in nondiabetic patients: Data from a randomized placebo-controlled trial. Arterioscler. Thromb. Vasc. Biol. 26, 845-850 (2006).
223. Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infraction and death from cardiovascular causes. N. Engl. J. Med. 356, 2457-2471 (2007).
224. Rosen CJ: The rosiglitazone story-lessons from an FDA Adviosry Committee Meeting. N. Engl. J. Med. 357, 844-846 (2007).
225. Dogrell SA: Does rosiglitazone increase cardiovascular outcomes? Expert Opin. Pharmacother. 8, 2665-2669 (2007).
226. Ginsberg HN, MacCallum PR: The obesity, metabolic syndrome, and Type 2 diabetes mellitus pandemic: Part I. Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and Type 2 diabetes mellitus. J. Cardiometab. Syndr. 4, 113-119 (2009).
227. Tenenbaum A, Motro M, Fisman EZ: Dual and pan-peroxisome proliferators-activated receptors (PPAR) co-agonism: The benzafibrate lessons. Cardiovasc. Diabetol. 14 4, 14, (2005).
228. Rubenstrunk A, Hanf R, Hun DW, Fruchart JC, Stales B: Safety issues and prospects for future generations of PPAR modulators. Biochim. Biophys. Acta 1771, 1065-1081 (2007).
229. Sharer BG, Billin AN: The next generation of PPAR drugs: Do we have the tools to find them? Biochim. Biophys. Acta 1771, 1082-1093 (2007).
230. Nissen SE, Wolski K, Topol EJ: Effect of muraglitizar on death and major adverse cardiovascular events in patients with Type 2 diabetes mellitus. JAMA 294, 2581-2586 (2005).
231. Bay H, McElhattan J, Bryzinski BS; On behalf of the Gallant 6 Study Group: A double-blind, randomized trial of tesaglitazar versus pioglitazone in patients with Type 2 diabetes mellitus. Diab. Vasc. Dis. Res. 4, 181-193 (2007).
232. Fagerberg B, Edwards S, Halmos T et al.: Tesaglitazar, a novel dual peroxisome proliferator-activated receptor a/g agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population. Diabetologia 48, 1716-1725 (2005).
233. Davidson MH, Armani A, McKenney JM, Jacobson TA: Safety considerations with fibrate therapy. Am. J. Cardiol. 99 (Suppl. 1), S3-S18 (2007).
234. Feldman PL, Lambert MH, Henke BR: PPAR modulators and PPAR pan agonists for metabolic diseases: The next generation of drugs targeting peroxisome proliferator-activated receptors? Curr. Top. Med. Chem. 8, 728-749 (2008).
235. Balint BL, Nagy L: Selective modulators of PPAR activity as new therapeutic tools in metabolic diseases. Endocr. Metab. Immune Disord. Drug Targets 6, 33-43 (2006).
236. Shelly W, Draper MW, Krishnan V, Wong M, Jaffe RB: Selective estrogen receptor modulators: An update on recent clinical findings. Obstet. Gynecol. Surv. 63, 163-181 (2008).
237. Peng J, Sengupta S, Jordan VC: Potential of selective estrogen receptor modulators as treatment. Anticancer Agents Med. Chem. 9, 481-499 (2009).
238. Cheung C, Akiyama TE, Ward JM et al.: Diminished hepatocellular proliferation in mice humanized for the nuclear receptor peroxisome proliferator-activated receptor a. Cancer Res. 64, 3849-3854 (2004).
239. Yang Q, Nagano T, Shah Y, Cheung C, Ito S, Gonzalez FJ: The PPARa-humanized mouse: A model to investigate species differences in liver toxicity mediated by PPARa. Toxicol. Sci. 101, 132-139 (2008).
240. Imai T, Takakuwa R, Marchand S et al.: Peroxisome proliferator-activated receptor g is required in mature white and brown adipocytes for their survival in the mouse. Proc. Natl Acad. Sci. USA 101, 4543-4547 (2004).
241. Kintscher U, Law RE: PPARg-mediated insulin sensitization: The importance of fat versus muscle. Am. J. Physiol. Endocrinol. Metab. 288, E287-E291 (2005).
242. He W, Barak Y, Hevener et al.: Adipose-specific peroxisome proliferator-activated receptor g knockout causes insulin resisatnce in fat and liver but not in muscle. Proc. Natl Acad. Sci. USA 100, 15712-15717 (2003).
243. Jones JR, Barrick C, Kim K-A et al.: Deletion of PPARg in a adipose tissues of mice protects against high fat diet-induced obesity and insulin resisatnce. Proc. Natl Acad. Sci. USA 102, 6207-6212 (2005).
244. Gavrilova O, Haluzik M, Matsusue K et al.: Liver peroxisome proliferator-activated receptor g contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J. Biol. Chem. 278, 34268-34276 (2003).
245. Matsusue K, Haluzik M, Lambert G et al.: Liver-specific disruption of PPARg in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. J. Clinical Invest. 111, 737-747 (2003).
246. Norris AW, Chen L, Fisher SJ et al.: Muscle-specific PPARg-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J. Clin. Invest. 112, 608-618 (2003).
247. Hevener AL, He W, Barak Y et al.: Muscle-specific PPARg deletion causes insulin resistance. Nature Med. 9, 1491-1497 (2003).
248. Zhong S, Ivashchenko CY, Russell MW, Milstone DS, Mortensen RM: Cardiomyocyte-specific knockout and agonist of peroxisome proliferator-activated receptor-g both induce cardiac hypertrophy in mice. Circ Res. 97, 372-379 (2005).
249. Chang L, Villacorta L, Zhang J et al.: Vascular smooth muscle cell-selective peroxisome proliferator-activated receptor-g deletion leads to hypotension. Circulation 119, 2161-2169 (2009).
250. Wang N, Symons JD, Zhang H et al.: Distinct functions of vascular endothelial and smooth muscle PPARg in regulation of blood oressure and vascular tone. Toxicol. Pathol. 37, 21-27 (2009).
251. Halabi CM, Beyer AM, de Lange W et al.: Interference with PPARg function in smooth muscle causes vascular dysfunction and hypertension. Cell Metab. 7, 215-226 (2008).
252. Kleinhenz JM, Kleinhenz DJ, You S et al.: Disruption of endothelial peroxisome proliferator-activated receptor-g reduces vascular nitric oxide production. Am. J. Physiol. Heart Circ. Physiol. 297, H1647-H1654 (2009).
253. Nicol CJ, Adachi M, Akiyama TE, Gonzalez FJ: PPARg in endothelial cells influences high fat diet-induced hypertension. Am. J. Hypertens. 18, 549-556 (2005).
254. Odegaard JI, Ricardo-Gonzalez RR, Goforth MH et al.: Macrophage-specific PPARg controls alternative activation and improve insulin resistance. Nature 447, 1116-1121 (2007).
255. Son NH, Park TS, Yamashita H et al.: Cradiomyocyte expression of PPARg leads to cardiac dysfunction in mice. J. Clin. Invest. 117, 2791-2801 (2007).
256. Amin RH, Mathews ST, Camp HS, Ding L, Left T: Selective activation of PPARg in skeletal muscle induces endogenous production of adiponectin and protects mice from diet-induced insulin resistance. Am. J. Physiol. Endocrinol. Metab. 298, E28-E37 (2009).
257. Zhang J, Fu M, Cui T et al.: Selective disruption of PPARγ2 impairs the development of adipose tissue and insulin sensitivity. Proc. Natl Acad. Sci. USA 101, 10703-10708 (2004).
258. Medina-Gomez G, Virtue S, Lelliott C et al.: The link between nutritional status and insulin sensitivity is dependent on the adipocyte-specific peroxisome proliferator-activated receptor-γ2 isoform. Diabetes 54, 1706-1718 (2005).
259. Koutnikova H, Cock TA, Watanabe M et al.: Compensation by the muscle limits the metabolic consequences of lipodystrophy in PPARg hypomorphic mice. Proc. Natl Acad. Sci. USA 100, 14457-114462 (2003).
260. Keech A, Simes RJ, Barter P et al.: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with Type 2 diabetes mellitus (the FIELD study): Randomized controlled trial. Lancet 26, 1849-1861 (2005).
261. Betteridge DJ, DeFronzo RA, Chilton RJ: PROactive: Time for critical appraisal. Eur. Heart J. 29, 969-983 (2008).
262. Erdman E, Dormandy J, Wilcox R, Massi-Benedetti M, Charbonnel B: PROactive: Pioglitazone in the treatment of Type 1 diabetes: Results of the PROactive study. Vasc. Health Risk Manag. 3, 355-370 (2007). (Pubitemid 47542597)
263. Kahn SE, Haffner SM, Heise MA et al.: Glycemic durability of rosiglitazone, metformin or glyburide monotherapy. N. Engl. J. Med. 355, 2427-2443 (2006).
264. Gerstein HC, Yusuf J, Bosch J et al.: DREAM (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication) trial investigators: Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomized controlled trial. Lancet 368, 1096-1105 (2006).
265. Buse JB: Atrion to Control Cardiovascular Risk in Diabetes (ACCORD) trial: Design and methods. Am. J. Cradiol. 99 (Suppl. 1), S21-S33 (2007).
266. Home PD, Pocock SJ, Beck-Nielsen H et al.: Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type diabetes (RECORD): A multicenter, randomized, open-label trial. Lancet 373, 2125-2135 (2009).
267. Nissen SE, Nicholls SJ, Wolski K et al.: Compariosn of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with Type 2 diabetes: The PERISCOPE randomized controlled trial. JAMA 299, 1561-1573 (2008). (Pubitemid 351482795)
268. Betterge DJ: CHICAGO, PERISCOPE and PROactive: CV risk modification in diabetes with pioglitazone. Fundam. Clin. Pharmacol. 23, 675-679 (2009).
269. Polonsky T, Mazzone T, Dvaidson M: The clinical implications of the CHICAGO study for the management of cardiovascular risk in patients with Type 2 diabetes. Trends Cardiovasc. Med. 19, 94-99 (2009).
270. Magee ME, Isley WL: Rationale, design, and methods for glycemic control in the Bypass Angioplasty Revascularization Investigation 2 diabetes (BARI 2D) trial. Am. J. Cardiol. 97(Suppl. 1), 20-30 (2006).